Glenmark Pharmaceuticals USA launches Travoprost Ophthalmic Solution USP, 0.004%

Glenmark's Travoprost Ophthalmic Solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z Ophthalmic Solution USP, 0.004% of Sandoz

FDA approves BridgeBio’s Attruby for ATTR-CM treatment

Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR

Edwards’ SAPIEN 3 Ultra RESILIA Valve demonstrates positive outcome

CAHO and Orchid Pharma partnership kicks off with conference on antimicrobial resistance

This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions

Merck announces pivotal phase 3 ZENITH trial evaluating WINREVAIR

WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality

Surendralal Karsanbhai elected to Merck Board of Directors

With the addition of Karsanbhai, the Merck board will consist of 13 members

USFDA accepts Blenrep combinations for treatment of relapsed/refractory multiple myeloma

If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse

JHU signs MoU with Ajit Isaac Foundation to bring essential palliative care services to rural India’s terminally ill

The collaboration offers opportunities for training, research fellowships, workshops and conferences at palliative care centers managed by Ajit Isaac Foundation

Sartorius Stedim Biotech opens center for bioprocess innovation in USA

New research labs and process development services to enable next generation therapeutics

Azenta obtains regulatory approval for clinical long-read whole genome sequencing test

Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory